Johnson & Johnson (JNJ) Expected to Post Earnings of $1.72 Per Share
Equities analysts expect that Johnson & Johnson (NYSE:JNJ) will post $1.72 earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Johnson & Johnson’s earnings, with the lowest EPS estimate coming in at $1.69 and the highest estimate coming in at $1.77. Johnson & Johnson posted earnings per share of $1.58 in the same quarter last year, which suggests a positive year over year growth rate of 8.9%. The company is expected to issue its next quarterly earnings results on Tuesday, January 23rd.
According to Zacks, analysts expect that Johnson & Johnson will report full-year earnings of $7.27 per share for the current fiscal year, with EPS estimates ranging from $7.20 to $7.30. For the next fiscal year, analysts anticipate that the business will post earnings of $7.80 per share, with EPS estimates ranging from $7.50 to $8.18. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period in the previous year, the company posted $1.68 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year.
JNJ has been the topic of a number of research reports. Morgan Stanley raised their price target on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 5th. Cowen and Company set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Thursday, August 24th. UBS AG restated a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a research note on Thursday, August 31st. BidaskClub downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Five investment analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $141.39.
Shares of Johnson & Johnson (NYSE JNJ) opened at 140.68 on Thursday. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $141.58. The company’s 50 day moving average price is $133.17 and its 200-day moving average price is $130.54. The company has a market capitalization of $377.58 billion, a price-to-earnings ratio of 23.80 and a beta of 0.78.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.39%. Johnson & Johnson’s payout ratio is 58.33%.
In other news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.19% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the company. Lynch & Associates IN lifted its position in shares of Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after acquiring an additional 841 shares in the last quarter. Oakbrook Investments LLC lifted its position in shares of Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after acquiring an additional 9,375 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Johnson & Johnson in the first quarter valued at about $1,731,000. Bollard Group LLC lifted its position in shares of Johnson & Johnson by 5.0% in the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock valued at $1,263,000 after acquiring an additional 459 shares in the last quarter. Finally, Adams Diversified Equity Fund Inc. lifted its position in shares of Johnson & Johnson by 278.0% in the second quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock valued at $32,001,000 after acquiring an additional 177,900 shares in the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.